Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Allergan Inc Raises Low End Of Prior FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates; Lowers FY 2013 EPS Guidance; Issues Q2 2013 Guidance; EPS Guidance Below Analysts' Estimates


Wednesday, 1 May 2013 09:00am EDT 

Allergan Inc announced that for fiscal 2013, it expects total product net sales between $5.975 billion and $6.200 billion and non-GAAP diluted earnings per share (EPS) attributable to stockholders from continuing operations between $4.70 and $4.76. For the second quarter of 2013, it expects total product net sales between $1.500 billion and $1.575 billion and non-GAAP diluted earnings per share (EPS) attributable to stockholders from continuing operations between $1.18 and $1.20. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $6.155 billion and EPS of $4.76 for fiscal 2013; revenue of $1.568 billion and EPS of $1.22 for second quarter of 2013. 

Company Quote

172.17
1.27 +0.74%
30 Jul 2014